Connect with us

Top Stories

Stock futures: U.S.-EU trade deal kicks off busy week: Live updates

Published

on


Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., July 25, 2025.

Jeenah Moon | Reuters

U.S. equity futures rose on Sunday evening as Wall Street prepared for an especially busy week that’ll bring earnings from several major tech companies, a key Federal Reserve meeting, President Donald Trump’s Aug. 1 tariff deadline and key inflation data.

Futures tied to the Dow Jones Industrial Average climbed 180 points, or 0.4%. S&P 500 futures were also higher by 0.3% and Nasdaq 100 futures added 0.4%.

The move comes after Trump announced Sunday that the U.S. has reached an agreement with the European Union to lower tariffs to 15%. The president had previously threatened 30% tariffs on most imported goods from the U.S.’s largest trading partner.

Wall Street is also coming off a winning week fueled by strong earnings and recent deals between the U.S. and other trading partners, including Japan and Indonesia.

On Friday, all three of the major averages finished the day and week with gains. The blue-chip Dow climbed 208.01 points, or 0.47%, to settle at 44,901.92. The broad market S&P 500 gained 0.40% to close at 6,388.64, marking its fifth consecutive day of closing records and 14th record close of the year. The tech-heavy Nasdaq Composite rose 0.24% to 21,108.32 for its 15th record close of the year.

“A healthy plethora of earnings beats, positive developments in U.S.-Japan trade relations, strong capex commentary, and a bullish “AI Action Plan” kept the enthusiasm of weeks’ past stronger than ever,” Nick Savone of Morgan Stanley’s Institutional Equity Division said in a note over the weekend.

“As we push through the bulk of S&P 500 companies still due to report, the lower bar heading into this season has admittedly kept spirits high, but stock reactions still look most principally rooted in forward guidance — especially as investors brace, time and again, for the impact of these trade headlines to flow through.”

The market is gearing up for the busiest week of earnings season. More than 150 companies in the S&P 500 are due to post their quarterly results, including “Magnificent Seven” names Meta Platforms and Microsoft on Wednesday, followed by Amazon and Apple on Thursday. Investors will be listening for companies’ comments on AI spending for direction on whether big investments in hyperscalers this year are justified.

This week, the Fed will also hold its two-day policy meeting, concluding on Wednesday. Although the central bank is expected to keep interest rates at their current target range of 4.25% to 4.5%, investors will be looking for clues about whether a rate cut could be on the table at the September meeting.

Tariffs and their effect on inflation will remain in focus on Thursday as traders get the June personal consumption expenditures price (PCE) index, the Fed’s preferred measure of inflation. The report is expected to show inflation rising to 2.4% from 2.3% year-over-year, according to FactSet, and to 0.31% from 0.14% on a monthly basis. 

Investors will also get a batch of jobs-related data this week, including the Job Openings and Labor Turnover Survey, or JOLTS, on Tuesday, ADP’s private payrolls report on Wednesday, initial jobless claims Thursday and, on Friday, the critical July jobs report. Economists polled by FactSet anticipate the U.S. economy added 115,000 jobs in July, down from 147,000 in June. The unemployment rate is expected to show a slight bump to 4.2% from 4.1%.



Source link

Top Stories

RFK Jr. faced tough hearing on vaccines, CDC changes : Shots

Published

on


Health and Human Services Secretary Robert F. Kennedy Jr. arrives to testify before the Senate Finance Committee at the Dirksen Senate Office Building on September 4, 2025 in Washington, DC.

Andrew Harnik/Getty Images


hide caption

toggle caption

Andrew Harnik/Getty Images

In a contentious Senate hearing marked by raised voices and heated exchanges, Health and Human Services Secretary Robert F. Kennedy Jr. faced calls to resign from Democrats and unexpected criticism from Republicans.

Several Republican senators brought up the legacy of President Donald Trump’s Operation Warp Speed, which sent a safe COVID vaccine to the public in record time, helping save millions of lives. They pushed Kennedy to explain his current approach to the shots and mRNA technology.

Under his leadership, the health agency cancelled hundreds of millions of dollars in research funding on mRNA technology for future vaccines, and the Food and Drug Administration limited access to the COVID shots, saying only people at high risk of complications from COVID or those over 65.

“President Trump deserves a Nobel Prize for Operation Warp Speed,” said Sen. Bill Cassidy, a Louisiana Republican and physician, whose vote was critical in Kennedy’s confirmation. He demanded Kennedy explain his changing stance on COVID vaccines, and said: “effectively, we’re denying people vaccine” — an assertion echoed by many physicians’ groups including the American Association of Pediatrics and the American Medical Association.

Cassidy had exacted assurances from Kennedy during his confirmation process in February that he would not restrict Americans’ access to vaccines, a promise the senator now accuses Kennedy of violating. Kennedy fired the entire 17-member Advisory Panel on Immunization Practices at the Centers for Disease Control and Prevention, replacing them with members Cassidy argued are largely unscientific vaccine skeptics with vested financial interests in suing vaccine makers.

Another Republican physician on the Senate Finance Committee, Dr. John Barrasso of Wyoming, joined Democrats in criticizing Kennedy for undermining vaccines.

“In your confirmation hearings, you promised to uphold the highest standards for vaccines. Since then, I’ve grown deeply concerned,” Barrasso told Kennedy at the hearing. “I’ve been hearing from many of my medical colleagues, and there are real concerns that safe, proven vaccines like measles, like hepatitis B and others, could be in jeopardy and that would put Americans at risk and reverse decades of progress.”

He accused Kennedy of politicizing vaccines further, and undermining public health.

CDC leadership change debated

Kennedy hotly defended his decisions and statements on vaccines and on changes at the CDC, arguing the agencies have historically relied on bad data.

“These changes were absolutely necessary adjustments to restore the agency to its role as the world’s gold standard public health agency,” he said. He claimed he had the backing of “scientists and doctors are supporting me all across the country.”

Senators also repeatedly asked Kennedy about his decision to push out newly confirmed CDC chief Susan Monarez. Though she was his own pick to lead the agency, he said Monarez was lying when she claimed she was fired from that job after only a month for insisting on rigorous scientific review.

In response to questions from Warren, Kennedy said: “I told her she had to resign because I asked her, ‘Are you a trustworthy person?’ And she said, ‘No.'”

Trump administration allies like Republican Ron Johnson of Wisconsin rushed to his defense, calling the senators’ pointed questions “abuse,” and lauding Kennedy for his attempts to overhaul health agencies.

Vaccine access arguments

Kennedy’s seven-and-a-half month tenure as Health Secretary is roiling the fields of science and health. His early sweeping changes included mass layoffs across the federal health and science agencies, from the FDA to the CDC to the National Institutes of Health.

Democratic senators took issue with these and other changes, as they and Kennedy accused each other of lying and manipulating data to serve political ends.

The committee’s ranking Democratic member Sen. Ron Wyden criticized Kennedy’s approach to vaccines: “I think Secretary Kennedy is dead set on making it harder for children to get vaccines and that kids are going to die because of it,” he said.

Sen. Elizabeth Warren, Democrat from Massachusetts, challenged Kennedy to “honor your promise that you made when you were looking to get confirmed” not to take away vaccines from people who want them. She said his recent moves to change the classification of the COVID vaccine do just that.

In response, Kennedy said “everybody can get access to them” for free, including those on Medicare and Medicaid, though the many contradictory statements have left many patients, doctors and insurers confused.

Kennedy said it was unclear the COVID vaccine had saved millions of lives — a data point generally accepted by scientists and doctors. But he also seemed to backtrack on assertions that he is “anti-vaccine,” arguing that there remain some unknown risks, even with long-approved vaccines.

Saying I’m anti-vaccine is like saying I’m anti-medicine,” Kennedy said, arguing he just wants more research to look into possible risks. “It doesn’t mean that I’m, you know, anti-vax. It just means I’m pro-science.”

His argument didn’t appear to sway the Democratic senators in attendance, with several calling for Kennedy to resign throughout the hearing.



Source link

Continue Reading

Top Stories

2026 Movie Plot, Cast Details Revealed

Published

on


Street Fighter — and its parent studio Legendary — have a new place to call home.

Legendary has inked a three-year pact with Paramount to distribute its movies, with the Capcom video game adaptation Street Fighter the first out of the gate. The Kitao Sakurai-directed feature now has a release date of Oct. 16, 2026.

The film is currently in production, with Paramount and Legendary releasing the first plot details for the movie, which will be set in 1993, the year the popular game Street Fighter II hit arcades.

Here’s the new logline: “Set in 1993, estranged Street Fighters Ryu (Andrew Koji) and Ken Masters (Noah Centineo) are thrown back into combat when the mysterious Chun-Li (Callina Liang) recruits them for the next World Warrior Tournament: a brutal clash of fists, fate, and fury. But behind this battle royale lies a deadly conspiracy that forces them to face off against each other and the demons of their past. And if they don’t, it’s GAME OVER!”

The Legendary deal, now official, was reported to be in talks on Aug. 18 and comes after its output deal with Sony expired at the end of 2024. Legendary’s former partner Warner Bros. will continue to distribute key franchises such as the eventual sequel to the nearly $1 billion hit A Minecraft Movie, as well as 2026’s third Dune and 2027’s Godzilla x Kong: Supernova.

The Street Fighter movie has a sprawling cast, including Noah Centineo as Ken Masters, Andrew Koji as Ryu, Callina Liang as Chun-Li, Joe “Roman Reigns” Anoa’i as Akuma, David Dastmalchian as M. Bison, Cody Rhodes as Guile, Andrew Schulz as Dan Hibiki, Eric André as Don Sauvage, Vidyut Jammwal as Dhalsim, with Curtis “50 Cent” Jackson as Balrog and Jason Momoa as Blanka.

It also stars Orville Peck as Vega, Olivier Richters as Zangief, Hirooki Goto as E. Honda, Rayna Vallandingham as Juli, Alexander Volkanovski as Joe, Kyle Mooney as Marvin and Mel Jarnson as Cammy.

“Legendary has built a reputation for ambitious, globally appealing films, and we’re excited to be partnering with them. Street Fighter is the perfect start to our collaboration, which we believe will be strong and lasting,” said Josh Greenstein, co-chair of Paramount Pictures and vice chair of platforms, and Dana Goldberg, Co-Chair of Paramount Pictures and Chair of Paramount Television.

Added Legendary CEO Josh Grode: “Partnering with David, Dana and Josh and their teams at Paramount marks an exciting new chapter for Legendary as we continue to pursue a diversified growth strategy—expanding our output, building new franchises, and creating more films for global audiences. This partnership is an extraordinary opportunity, and we look forward to working closely with Paramount on stories that will captivate and inspire moviegoers worldwide.”

This is just one of many key early moves made by David Ellison’s new Paramount, which lured Stranger Things creators the Duffer Bros. from Netflix, inked a $7.7 billion deal for UFC rights, and signed Will Smith’s Westbrook to a first-look film deal.



Source link

Continue Reading

Top Stories

Source – Amari Cooper tells Raiders he’s retiring from NFL

Published

on

By


Wide receiver Amari Cooper has informed the Las Vegas Raiders that he intends to retire just days before the team will open the 2025 season at New England, a source confirmed to ESPN on Thursday.

His decision comes after he told reporters last week, “trust me, I still got some juice left.” Cooper, 31, had signed with the Raiders late last month.

It ends what would have been a reunion with the franchise that drafted him with the fourth pick in 2015 when the team was based in Oakland.

It also will leave the Raiders with just four wide receivers on the 53-man roster: Jakobi Meyers, Tre Tucker, Dont’e Thornton Jr. and Jack Bech.

In 52 career games with the Silver and Black, Cooper totaled 225 catches for 3,183 yards and 19 touchdowns. He surpassed 1,000 yards in his first two seasons. The Raiders traded Cooper to the Dallas Cowboys during the 2018 season. The Cowboys then traded him to the Cleveland Browns in the 2022 offseason, and the Buffalo Bills acquired him last October from the Browns.

He finishes his career with 711 career receptions, 10,033 receiving yards and 64 touchdowns. He had seven seasons with at least 1,000 receiving yards, including a career-high 1,250 in 2023.

Cooper’s decision was first reported by NFL Network.

ESPN’s Ryan McFadden contributed to this report.



Source link

Continue Reading

Trending